Earth Science Tech (ETST) AI Stock Analysis

• Market Cap: $34.08M
• Dividend Yield: N/A
• Average Volume (3M): 44.92K
• Price to Earnings (P/E): 9.2
• Beta (1Y): 2.63
• Revenue Growth: 25.83%
• EPS Growth: 25.00%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): <0.01
• Shares Outstanding: 291,394,600
• 10 Day Avg. Volume: 74,750
• 30 Day Avg. Volume: 44,925
• PEG Ratio: 0.04
• Price to Book (P/B): 9.85
• Price to Sales (P/S): 1.15
• P/FCF Ratio: 10.48
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 0.92
• Enterprise Value/Gross Profit: 1.41
• Enterprise Value/Ebitda: 6.94
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: $0.12 ▼(-8.46% Downside)
• Action: Reiterated Date: 02/21/26
• Date: Action: Reiterated 02/21/26

The score is driven primarily by improved financial performance (profitability, low leverage, and positive cash flow) and a relatively low P/E. These positives are tempered by weak technicals (price below key moving averages with negative MACD) and the company’s recent deceleration in growth/free cash flow, despite supportive recent corporate updates.

Positive Factors

High margins & profitability

ETST’s high gross margin and consistent positive operating and net margins create durable operating leverage. These margins provide a cushion against input-cost swings, support reinvestment in growth areas (pharmacy/telemedicine), and make profitability less dependent on cyclical volume changes.

Conservative balance sheet & cash generation

A virtually debt-free balance sheet plus positive trailing-twelve-month operating and free cash flows give ETST financial flexibility to fund expansion, license approvals, and working capital needs without refinancing risk. This supports sustainable operations and optionality for strategic investments.

Diversified healthcare operations and traction

The company’s shift into compounding pharmacies, telemedicine and DTC brands diversifies revenue streams. Rapid telemedicine traction, geographic license expansion and industry reclassification to pharmaceuticals create structurally larger addressable markets and reduce single-product concentration risk.

Negative Factors

Slowing growth and FCF momentum

After an outsized jump, revenue and free-cash-flow growth have cooled materially. Slower top-line momentum and negative FCF growth trend reduce the margin of safety for reinvestment and raise execution demands to sustain profitability and deliver multi-period cash generation improvements.

Prior financial instability

Historical periods of losses, negative equity and earlier higher leverage indicate a limited track record of stability. This history increases downside risk if growth or margins deteriorate, as prior recovery required meaningful execution and capital actions that may need repeating.

Operational & governance complexity risk

Rapid diversification across regulated businesses raises integration, compliance and licensing burdens. With a small workforce (32 employees) and ongoing accounting consolidation complexity, execution and governance demands could strain resources and increase regulatory or operational missteps risk over the medium term.

Earth Science Tech Business Overview & Revenue Model

Company Description

Earth Science Tech, Inc., a biotechnology company, focuses on delivering nutraceuticals, bioceuticals, and dietary supplements in the areas of health, wellness, nutrition, supplement, cosmetic, and alternative medicine worldwide. The company focuses on delivering nutritional and dietary supplements for the treatment of chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea, aging, and overall wellness. Its products include hemp oils, vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods, and other products. The company markets its products in a range of formulations and delivery forms, including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs through its retail store, clinics, pharmacies, as well as through online. It also provides medical equipment and devices. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. The company was incorporated in 2010 and is headquartered in Doral, Florida.

How the Company Makes Money

ETST generates revenue primarily through the sale of its health and wellness products, which include CBD-infused supplements and topical solutions. The company has established key revenue streams by targeting both direct-to-consumer sales through its online platform and wholesale distribution to retailers and health practitioners. Additionally, ETST has engaged in strategic partnerships and collaborations with other companies in the biotech and cannabis sectors, enhancing its product offerings and market reach. The company's ability to innovate and adapt to consumer trends in the wellness industry, along with its commitment to high-quality standards, plays a significant role in its financial performance.

Earth Science Tech Financial Statement Overview

Summary

Financials are meaningfully improved: strong gross margin (~72%), positive operating profitability (EBIT ~9%, EBITDA ~10%), solid net margin (~8%), conservative leverage (debt-to-equity ~0.00), and positive TTM operating/free cash flow (~$3.0M/~$2.5M). Offsetting this, results have been historically volatile (including losses/negative equity in prior years) and recent growth/FCF momentum has cooled (TTM revenue growth ~3% and TTM FCF growth ~-10.6%).

Income Statement

ETST shows a sharp step-up in scale and profitability versus prior years, with TTM (Trailing-Twelve-Months) revenue of ~$34.9M and healthy gross margin (~72%). Operating profitability is positive (EBIT margin ~9% and EBITDA margin ~10%) and net margin is solid (~8%). The main weakness is growth normalization: after an outsized jump in 2024, revenue growth in the most recent periods is lower (TTM growth ~3%), and earlier history shows material volatility (including loss-making operating performance in 2021–2023).

Balance Sheet

The balance sheet is conservatively levered, with very low debt relative to equity in TTM (Trailing-Twelve-Months) (debt-to-equity ~0.00) and a larger asset base (~$8.1M) supported by meaningful equity (~$5.7M). Profitability on equity is strong in recent periods, reflecting the improved earnings profile. Key risk is historical instability: prior years included negative equity (2021–2022) and much higher leverage in 2023, highlighting that the current strength is relatively recent and may be sensitive to execution.

Cash Flow

Cash generation is positive, with TTM (Trailing-Twelve-Months) operating cash flow (~$3.0M) and free cash flow (~$2.5M). Cash flow broadly supports earnings, though free cash flow is below net income (about three-quarters of net income), and free cash flow declined versus the prior annual period (TTM free cash flow growth ~-10.6%). Earlier years showed negative operating and free cash flow, so while the current trend is constructive, consistency still looks developing.

Breakdown	TTM	Mar 2025	Mar 2024	Jun 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	34.87M	33.12M	11.95M	48.54K	14.12K	140.90K
Gross Profit	22.70M	24.30M	7.83M	22.06K	-8.52K	39.93K
EBITDA	4.63M	3.54M	1.04M	-300.48K	-224.28K	-4.30M
Net Income	3.49M	3.25M	812.14K	144.58K	6.66M	-4.47M
Balance Sheet
Total Assets	8.09M	7.07M	3.88M	2.69M	76.94K	64.56K
Cash, Cash Equivalents and Short-Term Investments	1.54M	2.12M	697.72K	35.76K	26.94K	16.16K
Total Debt	197.05K	401.24K	246.59K	974.11K	682.45K	650.44K
Total Liabilities	2.29M	3.22M	1.63M	1.61M	1.88M	5.09M
Stockholders Equity	5.73M	3.85M	2.25M	1.08M	-1.81M	-5.03M
Cash Flow
Free Cash Flow	2.50M	3.62M	1.18M	-1.01M	-166.39K	-196.69K
Operating Cash Flow	3.05M	4.37M	1.21M	-1.01M	-168.11K	-196.69K
Investing Cash Flow	-1.51M	-1.88M	-26.52K	0.00	1.71K	0.00
Financing Cash Flow	-1.64M	-1.72M	-517.88K	1.02M	173.18K	182.12K

Earth Science Tech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ETST, the sentiment is Negative. The current price of 0.13 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.14, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.82 is Neutral, neither overbought nor oversold. The STOCH value of 9.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ETST.

Earth Science Tech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ETST	66 Neutral	$34.08M	9.17	71.39%	―	25.83%	25.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TLPH	51 Neutral	$41.05M	-2.54	-86.48%	―	-90.04%	44.40%
CPIX	51 Neutral	$58.63M	-17.59	-13.08%	―	12.21%	69.91%
SCYX	45 Neutral	$33.02M	-1.32	-53.29%	―	-65.77%	38.61%
RMTI	42 Neutral	$37.02M	-5.83	-16.67%	―	-23.60%	-179.33%
COSM	40 Underperform	$13.62M	-0.56	-63.82%	―	―	―

Earth Science Tech Corporate Events

Earth Science Tech Appoints New Independent PCAOB Auditor

On February 17, 2026, Earth Science Tech, Inc., a strategic holding company focused on a diversified, vertically integrated health and wellness portfolio that includes compounding pharmacies, telemedicine platforms, healthcare facilities, real estate, and consumer kitchen products, announced a key change in its audit oversight. The company has been expanding rapidly across pharmacy compounding, telemedicine, and real estate, increasing the complexity of its consolidated accounting and sharpening the need for more robust financial governance.

On that date, Earth Science Tech disclosed that it had engaged Semple, Marchal & Cooper, LLP as its new independent PCAOB auditor, in what it described as a strategic upgrade to its financial governance infrastructure. The board concluded that Semple’s broader resources and specialized expertise were better suited to the company’s evolving operational scale and increasingly complex financial structure, signaling a move to strengthen audit capabilities and support ETST’s continued expansion trajectory.

The most recent analyst rating on (ETST) stock is a Buy with a $0.14 price target. To see the full list of analyst forecasts on Earth Science Tech stock, see the ETST Stock Forecast page.

Earth Science Tech Reports Strong Q3 2026 Financial Performance

Earth Science Tech, Inc., a diversified health and wellness holding company with compounding pharmacies, telemedicine platforms, healthcare facilities, and ancillary real estate and consumer brands, reported strong third fiscal quarter 2026 results for the period ended Dec. 31, 2025, highlighted by rising revenue and profitability. Revenue rose 14.1% year over year to $8.4 million, gross margin expanded to 76.3%, and net income jumped 341% to $910,000, while its Peaks telemedicine platform surpassed $2 million in revenue in under a year, the company generated positive operating cash flow, maintained a debt-free balance sheet, and continued share repurchases that reduced its share count by 3.6%, collectively signaling improved operating leverage and a stronger financial position for stakeholders.

Management noted that multiple operating units are now cash-flow positive despite seasonal and macro headwinds, with total assets up 14.5% since March 31, 2025 and working capital turning positive even as cash declined due to inventory investments to support higher sales. The company repurchased and retired 3.7 million shares over nine months, underscoring confidence in its portfolio strategy and earnings trajectory, while geographic expansion with up to 10 additional state licenses pending positions its pharmacy and telemedicine operations for further scale and margin gains.

The most recent analyst rating on (ETST) stock is a Buy with a $0.15 price target. To see the full list of analyst forecasts on Earth Science Tech stock, see the ETST Stock Forecast page.

Earth Science Tech Updates Industry Classification to Healthcare Pharmaceuticals

On January 6, 2026, Earth Science Tech, Inc. announced that it has formally directed financial data providers, news aggregators and brokerage platforms to update its industry classification to SIC 2834, reflecting its transition since 2022 from legacy CBD and cannabis operations to a fully healthcare- and pharmaceutical-focused company. The move follows the regulatory clearance of its 15c-211 filing and is intended to eliminate outdated database tags, align its market identity with its SEC-registered status and highlight its core operational pillars of pharmaceutical compounding via RxCompoundStore.com and Mister Meds and telemedicine delivery through Peaks Curative and DOConsultations, a clarification that could influence how investors, analysts and platforms assess and present ETST within the broader healthcare and pharmaceutical space.

The most recent analyst rating on (ETST) stock is a Hold with a $0.14 price target. To see the full list of analyst forecasts on Earth Science Tech stock, see the ETST Stock Forecast page.

Earth Science Tech Engages Hayden IR for Investor Outreach

On January 5, 2026, Earth Science Tech announced it had engaged investor relations firm Hayden IR to lead a more expansive investor outreach and capital markets communications program, following the company’s receipt of FINRA 15c2-11 clearance. The move comes as Earth Science Tech reports strong performance in the first half of fiscal 2026, including $17.8 million in revenue, $1.4 million in net income, more than $1 million in operating cash flow and gross margins exceeding 70%, and seeks to better communicate its growth strategy and operating leverage across its pharmacy, telemedicine and direct-to-consumer businesses to institutional and retail investors. Management and Hayden IR emphasized that clearer messaging, enhanced market awareness and the CEO’s substantial cash-funded share ownership are intended to improve recognition of the company’s earnings potential and support its broader market repositioning, with implications for increased investor engagement and potentially stronger capital markets support.

The most recent analyst rating on (ETST) stock is a Hold with a $0.14 price target. To see the full list of analyst forecasts on Earth Science Tech stock, see the ETST Stock Forecast page.